STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.6

Change

+1.10 (+0.51)%

Market Cap

USD 0.68B

Volume

452.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.12 (-0.26%)

USD 60.76B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.90 (+0.15%)

USD 13.44B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.37 (+0.09%)

USD 12.33B
WRD:PA HSBC MSCI World UCITS ETF

+0.05 (+0.13%)

USD 10.94B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-1.60 (-0.31%)

USD 8.88B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+0.93 (+0.38%)

USD 8.60B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.49 (+0.13%)

USD 7.71B
HHH:PA HSBC S&P 500 UCITS ETF

+0.08 (+0.14%)

USD 7.47B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.03 (+0.16%)

USD 6.81B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

+0.21 (+0.12%)

USD 5.39B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.91% 57% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.91% 57% F 59% D-
Trailing 12 Months  
Capital Gain 5.35% 27% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.35% 25% F 49% F
Trailing 5 Years  
Capital Gain 31.03% 51% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.03% 48% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 9.24% 56% F 61% D-
Dividend Return 9.24% 55% F 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.17% 75% C 93% A
Risk Adjusted Return 113.18% 92% A 97% N/A
Market Capitalization 0.68B 73% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike